Clinical trial · Interventional
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Phase II Study of Sorafenib and Zoledronic Acid in Advanced HCC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sorafenib ,an oral multikinase inhibitor targeting several tyrosine-kinase receptors with antiangiogenesis and antiproliferation of HCC, is the first approved target therapy for HCC. Zoledronic acid is used for treatment of bone metastasis of diverse malignant cancer. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. The objectives of the study is to evaluate the safety of Sorafenib combined with Zoledronic Acid and to evaluate overall survival and time to progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sorafenib and Zoledronic Acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sorafenib and Zoledronic Acid
- interventionNames
- Drug: Sorafenib and Zoledronic Acid
Primary outcomes (1)
- measure
- numbers of adverse events
- timeFrame
- 1 year
- description
- to evaluate the toxicity of sorafenib in combination with zoledronic acid
Secondary outcomes (1)
- measure
- Overall survival (OS), time to progression (TTP)
- timeFrame
- 1 year
- description
- to evaluate the efficacy of sorafenib in combination with zoledronic acid
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features * patient with unresectable primary hepatocellular carcinoma * Child-Pugh Class A or B, score ≤ 7 * ECOG score 0-2 * Expected survival time not less than 12 weeks * At least one tumor nodule with one uni-dimension of ≥ 1 cm * Peripheral platelet of or more than 50×10(9)/L * Peripheral hemoglobin of or more than 85g/L * Peripheral albumen of or more than 28g/L * Total bilirubin ≤3.0mg/dl * ALT and AST ≤ 5.0 x the upper limit of normal * Serum amylase ≤ 1.5x the upper limit of normal * Serum creatinine ≤ 1.5x upper limit of normal * PT-INR\<2.3 or PT prolong no more than 4s of normal Exclusion Criteria: * Congestive heart failure \> NYHA class 2 * History of active coronary disease( except myocardial infarction more than 6 months ago) * Receive anti-arrhythmia treatment(except β-receptor blocker,calcium channel blocker and digoxin) * uncontrollable hypertension * Active clinically serious infections (\> 2 NCI-CTC Version 3.0) * History of HIV infection * Inclined to hemorrhage or active hemorrhage with 1 month * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * Pregnant or breast-feeding.Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to enrolling in this portion of the study * Known or suspected allergy to any agent given in association with this trial * Concomitant anti-cancer therapy (except immunotherapy and Chinese traditional treatment) * Surgical operation within 4 weeks prior to enrolling in this portion of the study
References
Publications (0)
Data not yet available